echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Gan Lai announces that the THR-β agonist ASC41 achieves good results in overweight and obese subjects

    Gan Lai announces that the THR-β agonist ASC41 achieves good results in overweight and obese subjects

    • Last Update: 2021-03-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Gan Lai Pharmaceutical announced on February 21 that its liver-targeted prodrug ASC41 has achieved good results in clinical trials in overweight and obese subjects.


    In this randomized, double-blind, placebo-controlled clinical study, the study population consisted of 20 overweight and obese subjects with low-density lipoprotein cholesterol (LDL-C) greater than 110 mg/dL.


    During the 28-day treatment, ASC41 was relatively safe.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.